{"hands_on_practices": [{"introduction": "In clinical practice, a frequent point of confusion is the discrepancy between a point-of-care (POC) glucometer reading and a formal laboratory plasma glucose value. This exercise [@problem_id:5156121] delves into the underlying physiology, revealing that this difference is not random error but is predictable based on principles of fluid compartments and hematocrit. Mastering this concept is crucial for accurately interpreting glucose data and making correct diagnostic decisions, particularly in neonates and infants where high hematocrit levels are common.", "problem": "An $8$-month-old infant with poor oral intake presents with lethargy. A simultaneous pair of samples is obtained: a capillary whole-blood measurement on a point-of-care device reports $48\\,\\mathrm{mg/dL}$, while a central laboratory plasma glucose (hexokinase method) reports $55\\,\\mathrm{mg/dL}$. The hematocrit (red blood cell fraction by volume) measured from the same draw is $H=0.55$. You are asked to reconcile the difference in values and determine whether the point-of-care value plausibly reflects a whole-blood measurement that differs from plasma due to physiologic and analytic matrix effects.\n\nUse the following well-tested facts and core definitions as the fundamental base for your reasoning:\n\n- Hematocrit $H$ is the fraction of blood volume occupied by red blood cells (RBCs).\n- Glucose is a small, freely diffusible solute that equilibrates rapidly across the red blood cell membrane; its concentration is determined by the amount of glucose per unit volume of water.\n- The water fraction of plasma is approximately $f_{\\text{plasma}} \\approx 0.93$ (the remainder is proteins and lipids), and the water fraction of the red blood cell interior is approximately $f_{\\text{RBC}} \\approx 0.71$.\n- Point-of-care (POC) strip-based glucometers sample capillary whole blood and often display plasma-equivalent values by internal calibration; however, extreme hematocrits can alter strip filling and diffusion, introducing bias that depends on $H$ and the strip chemistry.\n\nWhich of the following statements most accurately explain and quantify the observed $10\\%$–$15\\%$ difference between the point-of-care capillary whole-blood measurement and the laboratory plasma glucose in this pediatric patient?\n\nA. If glucose distributes uniformly in the water phase of blood, then the whole-blood glucose concentration $c_{\\text{wb}}$ should be lower than plasma glucose $c_{\\text{plasma}}$ in proportion to the reduction in water fraction when red blood cells are present. Using $H=0.55$, $f_{\\text{plasma}}=0.93$, and $f_{\\text{RBC}}=0.71$, the expected ratio $c_{\\text{wb}}/c_{\\text{plasma}}$ is approximately $0.87$, which explains a difference like $48\\,\\mathrm{mg/dL}$ versus $55\\,\\mathrm{mg/dL}$.\n\nB. Plasma glucose is typically $10\\%$–$15\\%$ lower than whole-blood glucose because plasma proteins bind glucose, reducing the free glucose concentration reported by laboratory methods.\n\nC. At high hematocrit, point-of-care glucose oxidase or glucose dehydrogenase strip methods may underestimate glucose by an additional $5\\%$–$10\\%$ beyond the water-fraction effect due to reduced sample spreading and slower diffusion through the strip matrix; therefore, confirmatory plasma testing is necessary to avoid overcalling hypoglycemia at $H \\gtrsim 0.55$.\n\nD. The $7\\,\\mathrm{mg/dL}$ difference cannot be explained by hematocrit because glucose does not enter red blood cells; therefore, whole-blood and plasma glucose must be identical at steady state.\n\nE. Capillary versus venous sampling alone explains the $10\\%$–$15\\%$ difference: peripheral extraction during fasting reduces capillary glucose below venous by $10\\%$–$20\\%$ even in the absence of hematocrit effects.\n\nSelect all that apply.", "solution": "This problem requires analyzing the relationship between plasma glucose and whole-blood glucose, considering both physiological and analytical factors.\n\n**Physiological Relationship:**\nGlucose is dissolved in the water phase of blood. Whole blood consists of plasma and red blood cells (RBCs). The water fraction of plasma ($f_{\\text{plasma}}$) is higher than that of RBCs ($f_{\\text{RBC}}$).\n*   Given: $f_{\\text{plasma}} = 0.93$, $f_{\\text{RBC}} = 0.71$.\n*   Let $C_{\\text{plasma}}$ be the glucose concentration in plasma and $C_{\\text{wb}}$ be the glucose concentration in whole blood.\n*   The concentration of glucose in the water phase, $C_{\\text{water}}$, is constant throughout the blood. Thus, $C_{\\text{water}} = C_{\\text{plasma}} / f_{\\text{plasma}}$.\n*   The total glucose in a unit volume of whole blood is the sum of glucose in the plasma fraction and the RBC fraction. The volume fraction of plasma is $(1-H)$ and for RBCs is $H$.\n*   The total water volume fraction in whole blood is $(1-H)f_{\\text{plasma}} + H \\cdot f_{\\text{RBC}}$.\n*   The concentration in whole blood is $C_{\\text{wb}} = C_{\\text{water}} \\times (\\text{total water volume fraction}) = \\frac{C_{\\text{plasma}}}{f_{\\text{plasma}}} \\left[ (1-H)f_{\\text{plasma}} + H \\cdot f_{\\text{RBC}} \\right]$.\n*   The ratio of whole-blood to plasma glucose is therefore:\n    $$ \\frac{C_{\\text{wb}}}{C_{\\text{plasma}}} = \\frac{(1-H)f_{\\text{plasma}} + H \\cdot f_{\\text{RBC}}}{f_{\\text{plasma}}} = (1-H) + H \\frac{f_{\\text{RBC}}}{f_{\\text{plasma}}} $$\n*   Using the given hematocrit $H=0.55$:\n    $$ \\frac{C_{\\text{wb}}}{C_{\\text{plasma}}} = (1-0.55) + 0.55 \\left( \\frac{0.71}{0.93} \\right) \\approx 0.45 + 0.55(0.7634) \\approx 0.45 + 0.4199 \\approx 0.87 $$\n*   This means the whole-blood glucose concentration is expected to be about 87% of the plasma glucose concentration.\n*   Given $C_{\\text{plasma}} = 55\\,\\mathrm{mg/dL}$, the expected $C_{\\text{wb}} = 55 \\times 0.87 = 47.85\\,\\mathrm{mg/dL}$. This is very close to the point-of-care reading of $48\\,\\mathrm{mg/dL}$.\n\n**Analysis of the Options:**\n\n*   **A. Correct.** This statement correctly applies the water-fraction principle and calculates the expected ratio $C_{\\text{wb}}/C_{\\text{plasma}} \\approx 0.87$, which quantitatively accounts for the observed difference between $55\\,\\mathrm{mg/dL}$ (plasma) and $48\\,\\mathrm{mg/dL}$ (whole-blood equivalent).\n*   **B. Incorrect.** Plasma glucose is *higher* than whole-blood glucose because plasma has a higher water fraction than RBCs. Proteins do not bind glucose in a way that would lower the measurement; they primarily cause a volume displacement effect, which is already accounted for in the water fraction.\n*   **C. Correct.** This statement describes the well-documented \"hematocrit effect\" on point-of-care glucometers. At high hematocrit levels (infant normal is ~33-40%, so 55% is high), the increased viscosity and reduced plasma volume can impede sample flow on the test strip, leading to an underestimation of the true glucose value. This analytical bias can add to the physiological difference described in A, making it crucial to confirm low POC readings with laboratory plasma measurements in patients with abnormal hematocrits.\n*   **D. Incorrect.** This statement is based on the false premise that glucose does not enter red blood cells. Glucose freely enters RBCs via GLUT1 transporters.\n*   **E. Incorrect.** In the fasting state, there is minimal peripheral glucose uptake, so arterial, capillary, and venous glucose concentrations are nearly identical. A significant arterio-venous difference with lower capillary glucose is not expected. (In the post-prandial state, capillary glucose would be *higher* than venous glucose due to tissue uptake).\n\nSince both A and C provide accurate explanations for the observed results, they are both correct.", "answer": "$$\\boxed{AC}$$", "id": "5156121"}, {"introduction": "Once true hypoglycemia is confirmed, a critical diagnostic branch point is determining if it is a hyperinsulinemic state. This practice [@problem_id:5156149] focuses on the next crucial step: differentiating endogenous from exogenous sources of insulin. By applying the fundamental biochemical principle of proinsulin cleavage—which yields equimolar amounts of insulin and C-peptide—you will learn to dissect a \"critical sample\" of laboratory results to pinpoint the etiology, a core skill in pediatric endocrinology.", "problem": "A pediatric endocrinology team is consulted for a child with recurrent symptomatic hypoglycemia. To ground the analysis in core physiology, recall that pancreatic $\\beta$-cells synthesize proinsulin, which is enzymatically cleaved to yield insulin and connecting peptide (C-peptide) in an equimolar ratio of $1:1$. Exogenous insulin preparations contain insulin but no C-peptide. Pharmacologically, sulfonylureas act on ATP-sensitive potassium (K$_{\\text{ATP}}$) channels of $\\beta$-cells; by closing these channels, they depolarize the membrane, open voltage-dependent calcium channels, and increase endogenous insulin secretion. During hyperinsulinemic hypoglycemia, ketogenesis is suppressed, so serum $\\beta$-hydroxybutyrate is low. A sulfonylurea screen by Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) is used to detect drug exposure.\n\nA $9$-year-old boy is evaluated after an episode of confusion and diaphoresis with venous plasma glucose $= 32\\ \\mathrm{mg/dL}$. Blood is drawn at the time of hypoglycemia for serum insulin, C-peptide, $\\beta$-hydroxybutyrate, and a comprehensive sulfonylurea/meglitinide screen by LC-MS/MS. Which of the following laboratory constellations most specifically indicates exogenous insulin overdose rather than endogenous hyperinsulinism?\n\nA. Insulin $= 25\\ \\mu\\mathrm{U/mL}$, C-peptide $ 0.2\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.\n\nB. Insulin $= 28\\ \\mu\\mathrm{U/mL}$, C-peptide $= 3.0\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen positive for glipizide.\n\nC. Insulin $= 22\\ \\mu\\mathrm{U/mL}$, C-peptide $= 2.6\\ \\mathrm{ng/mL}$, proinsulin $= 30\\ \\mathrm{pmol/L}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.\n\nD. Insulin $= 3.0\\ \\mu\\mathrm{U/mL}$, C-peptide $ 0.2\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.\n\nSelect one option. Justify your choice by reasoning from the fundamental biosynthetic relationship between insulin and C-peptide and the mechanism of sulfonylureas. Assume all assays are analytically validated for contemporary insulin analog cross-reactivity unless otherwise indicated.", "solution": "The problem statement is evaluated for validity prior to any attempt at a solution.\n\n### Step 1: Extract Givens\n\nThe provided information is as follows:\n*   **Physiological  Pharmacological Principles:**\n    *   Pancreatic $\\beta$-cells synthesize proinsulin.\n    *   Proinsulin is enzymatically cleaved, yielding insulin and connecting peptide (C-peptide) in an equimolar ratio of $1:1$.\n    *   Exogenous insulin preparations contain insulin but no C-peptide.\n    *   Sulfonylureas act on ATP-sensitive potassium (K$_{\\text{ATP}}$) channels of $\\beta$-cells, closing them to increase endogenous insulin secretion.\n    *   During hyperinsulinemic hypoglycemia, ketogenesis is suppressed, so serum $\\beta$-hydroxybutyrate is low.\n    *   A sulfonylurea screen by Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) detects drug exposure.\n*   **Clinical Scenario:**\n    *   Patient is a $9$-year-old boy.\n    *   He presents with confusion and diaphoresis, and a venous plasma glucose of $32\\ \\mathrm{mg/dL}$.\n    *   Blood is drawn at the time of hypoglycemia for serum insulin, C-peptide, $\\beta$-hydroxybutyrate, and a sulfonylurea/meglitinide screen.\n*   **Question:**\n    *   Which of the listed laboratory constellations most specifically indicates exogenous insulin overdose rather than endogenous hyperinsulinism?\n*   **Assumption:**\n    *   All assays are analytically validated for contemporary insulin analog cross-reactivity.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is subjected to a critical review.\n\n*   **Scientifically Grounded:** The problem is based on fundamental and well-established principles of human physiology, endocrinology, and pharmacology. The relationship between proinsulin, insulin, and C-peptide is a cornerstone of hypoglycemia evaluation. The mechanism of sulfonylureas and the anti-ketogenic effect of insulin are also factually correct.\n*   **Well-Posed:** The problem is well-posed. It presents a clear clinical question—the differential diagnosis of hyperinsulinemic hypoglycemia—and provides sufficient background information and distinct sets of laboratory data to allow for a logical deduction of a single best answer.\n*   **Objective:** The problem uses objective, quantitative laboratory data and standard medical terminology. It is free from subjective or ambiguous language.\n*   **Completeness and Consistency:** The information provided is self-contained and sufficient to answer the question. There are no internal contradictions. The clinical scenario is plausible.\n*   **Realism:** The patient presentation and the laboratory values provided in the options are realistic for the differential diagnosis of pediatric hypoglycemia.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. It is scientifically sound, well-posed, objective, and presents a standard, non-trivial clinical reasoning task. The solution process may proceed.\n\n### Derivation of the Correct Answer\n\nThe core of the problem is to distinguish between two major categories of hyperinsulinemic hypoglycemia: endogenous hyperinsulinism and exogenous insulin administration. The key lies in the biosynthetic pathway of insulin.\n\n1.  **Endogenous Insulin Secretion:** The pancreas synthesizes proinsulin, which is cleaved into insulin and C-peptide. These two molecules are co-secreted into the portal circulation in an equimolar ($1:1$) ratio. Therefore, any condition that causes the pancreas to oversecrete insulin (e.g., an insulin-secreting tumor known as an insulinoma, or stimulation by a sulfonylurea drug) will result in high circulating levels of **both** insulin and C-peptide.\n\n2.  **Exogenous Insulin Administration:** Commercial insulin preparations contain purified insulin but do not contain C-peptide. When exogenous insulin is administered, it circulates in the blood and exerts its biological effects, including driving glucose into cells and causing hypoglycemia. The administered insulin can be measured by laboratory assays. Crucially, the resulting hypoglycemia provides strong negative feedback to the pancreatic $\\beta$-cells, suppressing the synthesis and secretion of endogenous proinsulin, insulin, and C-peptide. Therefore, the biochemical signature of exogenous insulin administration is a high level of measured insulin (from the injection) coupled with a low or suppressed level of C-peptide (due to pancreatic suppression).\n\n3.  **Ketogenesis:** Insulin is a potent inhibitor of ketogenesis. In any state of hyperinsulinemia, whether endogenous or exogenous, the production of ketone bodies (like $\\beta$-hydroxybutyrate) from fatty acids in the liver is suppressed. Thus, a low $\\beta$-hydroxybutyrate level confirms a hyperinsulinemic state but does not differentiate its cause. All valid options for hyperinsulinemic hypoglycemia should show low ketones.\n\n4.  **Sulfonylurea Screen:** This test directly identifies a specific cause of endogenous hyperinsulinism. A positive screen points to factitious hypoglycemia from sulfonylurea ingestion, while a negative screen rules it out.\n\nBased on this reasoning, the laboratory constellation most specific for exogenous insulin overdose is:\n*   High serum insulin\n*   Low (suppressed) serum C-peptide\n*   Low serum $\\beta$-hydroxybutyrate\n*   Negative sulfonylurea screen\n\n### Evaluation of Options\n\nLet's evaluate each option against this established profile. The patient's glucose is $32\\ \\mathrm{mg/dL}$, which is profoundly low. In a normal physiological response, insulin secretion should be suppressed to nearly undetectable levels (typically insulin $ 3\\ \\mu\\mathrm{U/mL}$ and C-peptide $ 0.2\\ \\mathrm{ng/mL}$). Any insulin level significantly above this threshold is considered inappropriate and indicative of hyperinsulinism.\n\n**A. Insulin $= 25\\ \\mu\\mathrm{U/mL}$, C-peptide $ 0.2\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.**\n*   **Insulin:** $25\\ \\mu\\mathrm{U/mL}$ is markedly elevated and inappropriate for the low glucose level.\n*   **C-peptide:** $ 0.2\\ \\mathrm{ng/mL}$ is suppressed, indicating that the pancreas is not the source of the high insulin.\n*   **$\\beta$-hydroxybutyrate:** $ 0.3\\ \\mathrm{mmol/L}$ is low, confirming a state of effective hyperinsulinemia.\n*   **Sulfonylurea screen:** Negative, ruling out this cause of endogenous stimulation.\n*   **Conclusion:** This combination of high insulin and suppressed C-peptide is the pathognomonic finding for exogenous insulin administration.\n*   **Verdict:** **Correct**.\n\n**B. Insulin $= 28\\ \\mu\\mathrm{U/mL}$, C-peptide $= 3.0\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen positive for glipizide.**\n*   **Insulin:** $28\\ \\mu\\mathrm{U/mL}$ is markedly elevated.\n*   **C-peptide:** $3.0\\ \\mathrm{ng/mL}$ is also elevated (a typical normal fasting range is $0.5 - 2.0\\ \\mathrm{ng/mL}$), consistent with endogenous secretion.\n*   **$\\beta$-hydroxybutyrate:** $ 0.3\\ \\mathrm{mmol/L}$ is low, consistent with hyperinsulinemia.\n*   **Sulfonylurea screen:** Positive for glipizide. This directly identifies the cause. Glipizide stimulates the pancreas to secrete both insulin and C-peptide.\n*   **Conclusion:** This profile indicates endogenous hyperinsulinism due to sulfonylurea ingestion.\n*   **Verdict:** **Incorrect**.\n\n**C. Insulin $= 22\\ \\mu\\mathrm{U/mL}$, C-peptide $= 2.6\\ \\mathrm{ng/mL}$, proinsulin $= 30\\ \\mathrm{pmol/L}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.**\n*   **Insulin:** $22\\ \\mu\\mathrm{U/mL}$ is markedly elevated.\n*   **C-peptide:** $2.6\\ \\mathrm{ng/mL}$ is also elevated, indicating an endogenous source.\n*   **Proinsulin:** $30\\ \\mathrm{pmol/L}$ is elevated, which can be seen with insulinomas due to inefficient prohormone processing.\n*   **$\\beta$-hydroxybutyrate:** $ 0.3\\ \\mathrm{mmol/L}$ is low, consistent with hyperinsulinemia.\n*   **Sulfonylurea screen:** Negative, ruling out drug ingestion.\n*   **Conclusion:** This profile of elevated insulin, C-peptide, and proinsulin is highly suggestive of an insulinoma, a form of endogenous hyperinsulinism.\n*   **Verdict:** **Incorrect**.\n\n**D. Insulin $= 3.0\\ \\mu\\mathrm{U/mL}$, C-peptide $ 0.2\\ \\mathrm{ng/mL}$, $\\beta$-hydroxybutyrate $ 0.3\\ \\mathrm{mmol/L}$, sulfonylurea screen negative.**\n*   **Insulin:** $3.0\\ \\mu\\mathrm{U/mL}$ is at the diagnostic threshold for hyperinsulinism. While not suppressed, it is not dramatically elevated as would be typical for a significant overdose.\n*   **C-peptide:** $ 0.2\\ \\mathrm{ng/mL}$ is suppressed.\n*   **$\\beta$-hydroxybutyrate:** $ 0.3\\ \\mathrm{mmol/L}$ is low.\n*   **Sulfonylurea screen:** Negative.\n*   **Conclusion:** This pattern is ambiguous. While the dissociation between a non-suppressed insulin and a suppressed C-peptide could suggest an exogenous source, the insulin level is not clearly elevated. Option A, with a markedly high insulin level of $25\\ \\mu\\mathrm{U/mL}$, presents a far more specific and classic picture of exogenous insulin overdose. The question asks for the constellation that *most specifically indicates* the diagnosis.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "5156149"}, {"introduction": "Effective management of persistent hypoglycemic disorders, such as Congenital Hyperinsulinism (CHI), requires a quantitative approach to intravenous glucose therapy. This problem [@problem_id:5156233] transitions from diagnosis to treatment, challenging you to apply a first-principles pharmacokinetic model to calculate adjustments in glucose infusion rates. By recognizing the direct proportionality between the infusion rate and steady-state glucose concentration, you will practice a vital skill for titrating therapy to safely achieve and maintain target glucose levels in critically ill children.", "problem": "A $3.2$ kg infant with Congenital Hyperinsulinism (CHI) presents with symptomatic hypoglycemia. Endogenous hepatic glucose production is suppressed by hyperinsulinemia and can be assumed negligible. The infant is receiving a continuous intravenous infusion of a $12.5\\%$ dextrose solution at a rate of $6$ mL/kg/hr. After sufficient time has elapsed to reach steady state, the plasma glucose concentration is measured at $55$ mg/dL and remains stable.\n\nFrom first principles, model plasma glucose under a constant intravenous input and first-order peripheral utilization as a single, well-mixed compartment with concentration $C(t)$ obeying the mass balance\n$$\n\\frac{dC(t)}{dt} \\;=\\; \\frac{R_{\\text{in}}}{V} \\;-\\; k\\,C(t),\n$$\nwhere $R_{\\text{in}}$ is the external glucose input rate in mg/kg/min, $V$ is the apparent volume of distribution in L/kg, and $k$ is the first-order utilization rate constant in min$^{-1}$. At steady state, the concentration $C_{\\text{ss}}$ satisfies $dC/dt = 0$.\n\nUsing only the definition of steady state and the concentration units of dextrose solutions, determine the intravenous infusion rate (in mL/kg/hr) of the same $12.5\\%$ dextrose solution required to maintain a target steady-state plasma glucose concentration of $70$ mg/dL, assuming endogenous hepatic glucose production remains negligible and peripheral utilization kinetics are unchanged from the observed steady state.\n\nExpress your final answer in mL/kg/hr and round your answer to four significant figures.", "solution": "The problem requires us to determine the new intravenous (IV) infusion rate of a dextrose solution needed to achieve a target plasma glucose concentration, based on an initial steady-state condition.\n\nThe dynamics of the plasma glucose concentration, $C(t)$, are described by the first-order linear ordinary differential equation:\n$$\n\\frac{dC(t)}{dt} = \\frac{R_{\\text{in}}}{V} - k\\,C(t)\n$$\nwhere $R_{\\text{in}}$ is the external glucose input rate (in mg/kg/min), $V$ is the apparent volume of distribution (in L/kg), and $k$ is the first-order utilization rate constant (in min$^{-1}$).\n\nThe problem specifies that the system is at a steady state, which is defined by the condition $\\frac{dC(t)}{dt} = 0$. Applying this condition to the given differential equation, we obtain the relationship between the steady-state concentration, $C_{\\text{ss}}$, and the glucose input rate, $R_{\\text{in}}$:\n$$\n0 = \\frac{R_{\\text{in}}}{V} - k\\,C_{\\text{ss}}\n$$\nRearranging this equation to solve for $C_{\\text{ss}}$ yields:\n$$\nk\\,C_{\\text{ss}} = \\frac{R_{\\text{in}}}{V}\n$$\n$$\nC_{\\text{ss}} = \\frac{R_{\\text{in}}}{kV}\n$$\nThe problem states that the peripheral utilization kinetics are unchanged for the new target concentration. This implies that the rate constant $k$ is constant. The apparent volume of distribution $V$ is an intrinsic physiological parameter of the infant and is also assumed to be constant. Therefore, the term $\\frac{1}{kV}$ is a constant of proportionality. This means that the steady-state plasma glucose concentration $C_{\\text{ss}}$ is directly proportional to the glucose infusion rate $R_{\\text{in}}$. We can write this relationship as $C_{\\text{ss}} \\propto R_{\\text{in}}$.\n\nNext, we must relate the glucose infusion rate, $R_{\\text{in}}$ (in mg/kg/min), to the intravenous fluid infusion rate, which we will denote as $I$ (in mL/kg/hr). The solution being infused is a $12.5\\%$ dextrose solution. By definition, a $w/v$ percentage concentration of $12.5\\%$ means there are $12.5$ grams of dextrose per $100$ milliliters of solution. Let's convert this to units of mg/mL.\n$$\n\\text{Concentration } (\\rho_G) = \\frac{12.5 \\text{ g}}{100 \\text{ mL}} = \\frac{12.5 \\times 1000 \\text{ mg}}{100 \\text{ mL}} = 125 \\frac{\\text{mg}}{\\text{mL}}\n$$\nThe rate of glucose administration, $R_{\\text{in}}$, is the product of the fluid infusion rate, $I$, and the concentration of the fluid, $\\rho_G$. We must also include a time unit conversion from hours to minutes.\n$$\nR_{\\text{in}} \\left[\\frac{\\text{mg}}{\\text{kg} \\cdot \\text{min}}\\right] = I \\left[\\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}}\\right] \\times \\rho_G \\left[\\frac{\\text{mg}}{\\text{mL}}\\right] \\times \\frac{1 \\text{ hr}}{60 \\text{ min}}\n$$\nSince the dextrose concentration $\\rho_G$ and the conversion factor $\\frac{1}{60}$ are constant, the glucose infusion rate $R_{\\text{in}}$ is directly proportional to the IV fluid rate $I$. We can write this as $R_{\\text{in}} \\propto I$.\n\nSince we have established that $C_{\\text{ss}} \\propto R_{\\text{in}}$ and $R_{\\text{in}} \\propto I$, by transitivity, we can conclude that the steady-state glucose concentration is directly proportional to the IV fluid infusion rate:\n$$\nC_{\\text{ss}} \\propto I\n$$\nThis proportionality allows us to set up a simple ratio to find the new required infusion rate, $I_2$, based on the initial infusion rate, $I_1$, and the corresponding initial and target steady-state concentrations, $C_{\\text{ss},1}$ and $C_{\\text{ss},2}$.\n$$\n\\frac{I_2}{I_1} = \\frac{C_{\\text{ss},2}}{C_{\\text{ss},1}}\n$$\nSolving for $I_2$:\n$$\nI_2 = I_1 \\times \\frac{C_{\\text{ss},2}}{C_{\\text{ss},1}}\n$$\nThe problem provides the following values:\nInitial fluid infusion rate, $I_1 = 6 \\text{ mL/kg/hr}$.\nInitial steady-state glucose concentration, $C_{\\text{ss},1} = 55 \\text{ mg/dL}$.\nTarget steady-state glucose concentration, $C_{\\text{ss},2} = 70 \\text{ mg/dL}$.\n\nSubstituting these values into the equation for $I_2$:\n$$\nI_2 = 6 \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}} \\times \\frac{70 \\text{ mg/dL}}{55 \\text{ mg/dL}}\n$$\nThe units of concentration (mg/dL) cancel out, as expected.\n$$\nI_2 = 6 \\times \\frac{70}{55} \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}}\n$$\nSimplifying the fraction:\n$$\nI_2 = 6 \\times \\frac{14}{11} \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}} = \\frac{84}{11} \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}}\n$$\nNow, we calculate the numerical value:\n$$\nI_2 = 7.636363... \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}}\n$$\nThe problem asks for the answer to be rounded to four significant figures.\n$$\nI_2 \\approx 7.636 \\frac{\\text{mL}}{\\text{kg} \\cdot \\text{hr}}\n$$\nThis is the required intravenous infusion rate of the $12.5\\%$ dextrose solution to achieve the target plasma glucose level of $70$ mg/dL.", "answer": "$$\n\\boxed{7.636}\n$$", "id": "5156233"}]}